It is the ninth Humira biosimilar approved by the FDA and the fourth to receive interchangeability status. The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the ...

Humira (adalimumab) is a prescription drug that’s used to treat certain conditions, such as rheumatoid arthritis. Humira can cause side effects that range from mild to serious. Examples include ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

The price you pay for Humira (adalimumab) may depend on factors such as the form you take, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to ...

LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab). The decision allows Yuflyma to be ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to ...

Learn More » Here is what you need to know. AbbVie's transition away from Humira has been masterful If you've followed AbbVie in the past, it spent years reaping the windfall of Humira ...